Matches in Wikidata for { <http://www.wikidata.org/entity/Q85329303> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- Q85329303 description "2014 թվականին հրատարակված գիտական հոդված" @default.
- Q85329303 description "article scientifique publié en 2014" @default.
- Q85329303 description "artikull shkencor i botuar më 01 janar 2014" @default.
- Q85329303 description "artículu científicu espublizáu en xineru de 2014" @default.
- Q85329303 description "im Jahr 2014 veröffentlichter wissenschaftlicher Artikel" @default.
- Q85329303 description "scientific article published on 01 January 2014" @default.
- Q85329303 description "wetenschappelijk artikel" @default.
- Q85329303 description "наукова стаття, опублікована в січні 2014" @default.
- Q85329303 description "научна статия" @default.
- Q85329303 name "Lung-cancer immunotherapeutics on the horizon as Opdivo advances through Phase 2" @default.
- Q85329303 name "Lung-cancer immunotherapeutics on the horizon as Opdivo advances through Phase 2" @default.
- Q85329303 name "Lung-cancer immunotherapeutics on the horizon as Opdivo advances through Phase 2" @default.
- Q85329303 type Item @default.
- Q85329303 label "Lung-cancer immunotherapeutics on the horizon as Opdivo advances through Phase 2" @default.
- Q85329303 label "Lung-cancer immunotherapeutics on the horizon as Opdivo advances through Phase 2" @default.
- Q85329303 label "Lung-cancer immunotherapeutics on the horizon as Opdivo advances through Phase 2" @default.
- Q85329303 prefLabel "Lung-cancer immunotherapeutics on the horizon as Opdivo advances through Phase 2" @default.
- Q85329303 prefLabel "Lung-cancer immunotherapeutics on the horizon as Opdivo advances through Phase 2" @default.
- Q85329303 prefLabel "Lung-cancer immunotherapeutics on the horizon as Opdivo advances through Phase 2" @default.
- Q85329303 P1433 Q85329303-5C4F5A3A-9580-40AB-9CF5-3DCBCF5AFEA9 @default.
- Q85329303 P1476 Q85329303-CBCDBD13-F2E1-4BEB-A391-8B55DC5F1D14 @default.
- Q85329303 P304 Q85329303-B2CA3327-8C01-4482-9A5E-30C6C70342F7 @default.
- Q85329303 P31 Q85329303-11F0BF41-9B68-40C2-824F-F0708530F3F7 @default.
- Q85329303 P433 Q85329303-E1CDE193-DDFD-465B-87E7-93C9AE466BD3 @default.
- Q85329303 P478 Q85329303-6CAB83E2-7862-4C3A-B408-E89EC8386CB6 @default.
- Q85329303 P577 Q85329303-29AA5D8A-A0A2-4630-885D-E407E74FE6E7 @default.
- Q85329303 P698 Q85329303-DA63C984-2A35-4081-B413-E75FC0A839B2 @default.
- Q85329303 P921 Q85329303-F896A145-8421-4CC8-B058-5B8F9BA0E6BD @default.
- Q85329303 P698 26052584 @default.
- Q85329303 P1433 Q21072749 @default.
- Q85329303 P1476 "Lung-cancer immunotherapeutics on the horizon as Opdivo advances through Phase 2" @default.
- Q85329303 P304 "3427" @default.
- Q85329303 P31 Q13442814 @default.
- Q85329303 P433 "12" @default.
- Q85329303 P478 "10" @default.
- Q85329303 P577 "2014-01-01T00:00:00Z" @default.
- Q85329303 P698 "26052584" @default.
- Q85329303 P921 Q1427096 @default.